4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read More
Super Simple Investing Method That Made Buffett Rich
A lot is made of Buffett’s approach to investing but it can be simplified to a level even a 12-year old understands.
While it’s easy for sophisticated investors to get caught up in the weeds of price-to-earnings multiples, competitive advantages, book values, and balance sheets, there is arguably a much simpler approach Buffett has taken to investing that can be applied by just about any investor willing to spend a little time musing on the topic.
» Read more about: Super Simple Investing Method That Made Buffett Rich »
Read More
Why Buffett’s Latest Move Is So Scary
Buffett says he doesn’t time the market but when you look at his past moves, it’s clear that the old sage uses metrics that happen to coincide well with smart market timing.
Take his purchases at the bottom of the market in 2008-09 when he deployed almost 50% of his cash pile within the space of just a few weeks in October 2008.
» Read more about: Why Buffett’s Latest Move Is So Scary »
Read More
Avoid This Semi Stock Like The Plague?
On August 1st, Intel released its Q2 earnings report, much to the chagrin of longtime shareholders.
In the release, the company reported a 1% year-over-year revenue drop alongside a quarterly net loss of $1.6 billion. Much more concerning was the company’s plan for a cost reduction campaign that involved layoffs, reduced capital expenditures and a suspension of the company’s quarterly dividend.
» Read more about: Avoid This Semi Stock Like The Plague? »
Read More
Which AI Stock Is Best?
The artificial intelligence gold rush has created winners and wannabes. Two companies at the center of that storm, C3.ai and CoreWeave, have taken very different paths in the race to capitalize on enterprise AI demand. Both play crucial roles in the AI stack, one builds the software brains, the other supplies the computational muscle. But only one of them has the market’s full attention.
» Read more about: Which AI Stock Is Best? »
Read MoreThe Burst
Micron Is Down 42%, Why It Might Be a Screaming Buy?
Micron Technology (NASDAQ: MU) is no stranger to volatility, but its recent price action has been brutal even by semiconductor standards. Since peaking in June of last year, the stock has tumbled 42%. And nearly 30% of that decline happened in just the past month.
So, is this a falling knife or an undervalued gem in the chip sector?
» Read more about: Micron Is Down 42%, Why It Might Be a Screaming Buy? »
Read MoreThe Spotlight
10 Billion Reasons To Own This Recession-Proof Stock
With concerns of an impending recession looming large and Goldman Sachs pivoting away from momentum stocks to value stocks, one stock that may fit the bill is Procter & Gamble.
Although the share price has been somewhat volatile subsequent to fiscal Q4 2024 earnings results, P&G bounced back nicely to make an assault on all-time highs.
» Read more about: 10 Billion Reasons To Own This Recession-Proof Stock »
Read MoreThe Daily
Tesla Stock Up 120% in Past 5 Years
© Deemerwha studio / Shutterstock.com
Tesla Inc. (NASDAQ: TSLA) stock recently reached an all-time high. After wavering earlier this year, it is up 120% over the past five years. That compares to the S&P 500’s gain of 87% in that time. This is despite slow sales,